JP6966996B2 - Ｐｃｎａ阻害剤 - Google Patents

Ｐｃｎａ阻害剤 Download PDF

Info

Publication number
JP6966996B2
JP6966996B2 JP2018514282A JP2018514282A JP6966996B2 JP 6966996 B2 JP6966996 B2 JP 6966996B2 JP 2018514282 A JP2018514282 A JP 2018514282A JP 2018514282 A JP2018514282 A JP 2018514282A JP 6966996 B2 JP6966996 B2 JP 6966996B2
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
nhc
alkyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018514282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500315A (ja
JP2019500315A5 (enExample
Inventor
マルカス，リンダ・エイチ
ホーン，デイビッド
ヒッキー，ロバート・ジェイ
グー，ロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58289682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6966996(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by City of Hope filed Critical City of Hope
Publication of JP2019500315A publication Critical patent/JP2019500315A/ja
Publication of JP2019500315A5 publication Critical patent/JP2019500315A5/ja
Priority to JP2021172158A priority Critical patent/JP7399925B2/ja
Application granted granted Critical
Publication of JP6966996B2 publication Critical patent/JP6966996B2/ja
Priority to JP2023205089A priority patent/JP7690553B2/ja
Priority to JP2025088605A priority patent/JP2025128193A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2018514282A 2015-09-17 2016-09-16 Ｐｃｎａ阻害剤 Active JP6966996B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021172158A JP7399925B2 (ja) 2015-09-17 2021-10-21 Ｐｃｎａ阻害剤
JP2023205089A JP7690553B2 (ja) 2015-09-17 2023-12-05 Ｐｃｎａ阻害剤
JP2025088605A JP2025128193A (ja) 2015-09-17 2025-05-28 Ｐｃｎａ阻害剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562220014P 2015-09-17 2015-09-17
US62/220,014 2015-09-17
US201662313592P 2016-03-25 2016-03-25
US62/313,592 2016-03-25
US201662340964P 2016-05-24 2016-05-24
US62/340,964 2016-05-24
PCT/US2016/052310 WO2017049206A1 (en) 2015-09-17 2016-09-16 Pcna inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021172158A Division JP7399925B2 (ja) 2015-09-17 2021-10-21 Ｐｃｎａ阻害剤

Publications (3)

Publication Number Publication Date
JP2019500315A JP2019500315A (ja) 2019-01-10
JP2019500315A5 JP2019500315A5 (enExample) 2019-10-31
JP6966996B2 true JP6966996B2 (ja) 2021-11-17

Family

ID=58289682

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018514282A Active JP6966996B2 (ja) 2015-09-17 2016-09-16 Ｐｃｎａ阻害剤
JP2021172158A Active JP7399925B2 (ja) 2015-09-17 2021-10-21 Ｐｃｎａ阻害剤
JP2023205089A Active JP7690553B2 (ja) 2015-09-17 2023-12-05 Ｐｃｎａ阻害剤
JP2025088605A Pending JP2025128193A (ja) 2015-09-17 2025-05-28 Ｐｃｎａ阻害剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021172158A Active JP7399925B2 (ja) 2015-09-17 2021-10-21 Ｐｃｎａ阻害剤
JP2023205089A Active JP7690553B2 (ja) 2015-09-17 2023-12-05 Ｐｃｎａ阻害剤
JP2025088605A Pending JP2025128193A (ja) 2015-09-17 2025-05-28 Ｐｃｎａ阻害剤

Country Status (11)

Country Link
US (5) US10550070B2 (enExample)
EP (2) EP4616910A3 (enExample)
JP (4) JP6966996B2 (enExample)
KR (2) KR20250026875A (enExample)
CN (2) CN108348512B (enExample)
AU (3) AU2016324158B2 (enExample)
CA (1) CA2999080C (enExample)
ES (1) ES3040726T3 (enExample)
IL (4) IL282400B (enExample)
MX (2) MX382996B (enExample)
WO (1) WO2017049206A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10420840B2 (en) * 2015-04-10 2019-09-24 Rll, Llc Anticancer therapeutic agents
MX382996B (es) * 2015-09-17 2025-03-13 Hope City Inhibidores de pcna
WO2019133501A1 (en) * 2017-12-29 2019-07-04 Groupon, Inc. Methods and systems for generating a supply index indicative of a quality of available supply
US11551247B1 (en) 2017-12-29 2023-01-10 Groupon, Inc. Methods and systems for determining a travel propensity configured for use in the generation of a supply index indicative of a quality of available supply
AU2022264802A1 (en) * 2021-04-30 2023-10-12 City Of Hope Pcna inhibitors and egfr inhibitors for cancer treatment
KR20240158305A (ko) * 2022-03-07 2024-11-04 시티 오브 호프 Pcna 억제제 및 이의 용도
WO2025054318A1 (en) * 2023-09-06 2025-03-13 City Of Hope Pcna inhibitors and uses thereof
CN117603081A (zh) * 2023-11-28 2024-02-27 沈阳药科大学 N-(2-((2-(3-甲氧基苯氧基)苯基)氨基)-2-乙酰氧基)-1-萘胺的制备方法
CN120097860A (zh) * 2023-12-05 2025-06-06 杜心赟 增殖细胞核抗原抑制剂、其制备方法、其中间体、其药物组合物和用途
WO2025184571A1 (en) * 2024-03-01 2025-09-04 City Of Hope Pcna inhibitors for the treatment of myc family associated cancers
CN118546074B (zh) * 2024-05-27 2025-06-06 安徽贝克制药股份有限公司 一种氘代增殖细胞核抗原抑制剂及其制备方法和其应用
CN118459363B (zh) * 2024-05-27 2024-12-17 安徽贝克制药股份有限公司 一种氟取代增殖细胞核抗原抑制剂及其制备方法和其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1295611A (en) * 1916-07-29 1919-02-25 Moritz D Schwartz Metatarsal support.
US1298989A (en) * 1918-11-14 1919-04-01 Reed Foundry & Machine Co Tractor-plow.
US4030910A (en) * 1974-01-22 1977-06-21 The Dow Chemical Company Substituted pyridinyloxy(thio)phenyl -acetamides, -ureas and urea derivatives, herbicidal compositions and methods containing same
US4269829A (en) * 1979-06-18 1981-05-26 Rohm And Haas Company Method and composition for treating helminths containing O,O-dialkyl-N-(substituted phenyl)aminothiocarbonyl phosphoramidates
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
FR2723739B1 (fr) * 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
US5783597A (en) 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US6258822B1 (en) * 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
PT1064298E (pt) * 1998-03-19 2009-01-02 Vertex Pharma Inibidores de caspasas
US6090854A (en) 1998-03-20 2000-07-18 Bristol-Meyers Company Aryloxyanilides and related compounds
AU2001260661A1 (en) * 2000-05-30 2001-12-11 Chugai Seiyaku Kabushiki Kaisha Compounds exhibiting thrombopoietin-like activities
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
GB0319126D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
US20070208166A1 (en) 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200745025A (en) * 2005-12-29 2007-12-16 Schering Ag Amide inhibitors of leukotriene A4 hydrolase
JP2012505920A (ja) * 2008-10-17 2012-03-08 エグゼリクシス， インコーポレイテッド スフィンゴシン１リン酸塩受容体拮抗薬
AU2009305565A1 (en) * 2008-10-17 2010-04-22 Exelixis, Inc. Synergistic combination of sphingosine-1-phosphate receptor antagonists and antimicrotubule agents
GB201011411D0 (en) 2010-07-06 2010-08-18 St Georges Hosp Medical School Therapeutic compounds and their use
CA2802641C (en) * 2010-07-13 2019-03-12 Nidhi Arora Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators
CN103189063B (zh) * 2010-11-01 2016-10-19 宾夕法尼亚州研究基金会 治疗组合物和方法
US20130345231A1 (en) * 2011-03-23 2013-12-26 Indiana University Research And Technology Corporation Anticancer therapeutic agents
CA2940272C (en) * 2014-02-28 2022-03-29 Tohoku University Amide derivative
MX382996B (es) * 2015-09-17 2025-03-13 Hope City Inhibidores de pcna

Also Published As

Publication number Publication date
US11345656B2 (en) 2022-05-31
US10550070B2 (en) 2020-02-04
IL294381B1 (en) 2023-03-01
IL282400A (en) 2021-06-30
CN108348512A (zh) 2018-07-31
US20240343682A1 (en) 2024-10-17
CA2999080C (en) 2023-11-14
KR20180069817A (ko) 2018-06-25
EP3349754A1 (en) 2018-07-25
US20210078938A1 (en) 2021-03-18
EP4616910A2 (en) 2025-09-17
IL258174B (en) 2020-08-31
EP3349754B9 (en) 2025-10-22
US12435030B2 (en) 2025-10-07
JP2019500315A (ja) 2019-01-10
KR102768838B1 (ko) 2025-02-14
IL276115A (en) 2020-08-31
US20180339960A1 (en) 2018-11-29
WO2017049206A1 (en) 2017-03-23
KR20250026875A (ko) 2025-02-25
MX382996B (es) 2025-03-13
AU2016324158A1 (en) 2018-04-12
AU2023201501A1 (en) 2023-04-13
JP7690553B2 (ja) 2025-06-10
EP3349754C0 (en) 2025-07-16
CN108348512B (zh) 2021-09-03
JP7399925B2 (ja) 2023-12-18
US12054447B2 (en) 2024-08-06
BR112018005331A2 (pt) 2018-10-09
IL258174A (en) 2018-05-31
JP2025128193A (ja) 2025-09-02
AU2023201501B2 (en) 2024-07-04
MX2018003301A (es) 2019-02-07
IL276115B (en) 2021-05-31
HK1258793A1 (en) 2019-11-22
CA2999080A1 (en) 2017-03-23
JP2024028846A (ja) 2024-03-05
IL294381B2 (en) 2023-07-01
NZ740817A (en) 2024-03-22
MX2021006326A (es) 2022-12-16
US10913706B2 (en) 2021-02-09
US20200216386A1 (en) 2020-07-09
AU2020270487A1 (en) 2020-12-17
JP2022028665A (ja) 2022-02-16
AU2020270487B2 (en) 2022-12-15
ES3040726T3 (en) 2025-11-04
AU2016324158B2 (en) 2020-08-27
IL294381A (en) 2022-08-01
EP4616910A3 (en) 2025-11-05
US20220340516A1 (en) 2022-10-27
EP3349754A4 (en) 2019-03-20
IL282400B (en) 2022-08-01
CN113620833A (zh) 2021-11-09
EP3349754B1 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
JP6966996B2 (ja) Ｐｃｎａ阻害剤
JP6933644B2 (ja) アンドロゲン受容体拮抗薬
KR20240158305A (ko) Pcna 억제제 및 이의 용도
HK40055283A (en) Pcna inhibitors
HK1258659B (en) Pcna inhibitors
HK1258659A1 (en) Pcna inhibitors
HK1258793B (en) Pcna inhibitors
BR112018005331B1 (pt) Inibidores de pcna
EA048301B1 (ru) Ингибиторы pcna
EA040083B1 (ru) Соединения, ингибирующие pcna, фармацевтические композиции и способы лечения заболеваний, связанных с активностью pcna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210922

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211022

R150 Certificate of patent or registration of utility model

Ref document number: 6966996

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250